Roche Diagnostics leaps 7%; ERBA swings to a profit;

@FierceMedDev: Med tech VC Santé wraps up a $139M healthcare fund. Piece | Follow @FierceMedDev

@VarunSaxena2: Abbott's diabetes biz hit with its third Class I recall in a year. News | Follow @VarunSaxena2

@EmilyWFierce: Devices approved for pediatric use weren't tested in children first, new study finds. More | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Story | Follow @MichaelGFierce

> Roche's ($RHHBY) diagnostics revenue jumped 7% in the first quarter, pulling in about $2.8 billion. News

> ERBA Diagnostics ($ERB) swung to a small profit in 2013 after taking a $1.5 million loss the previous year. Story

> Kalila Medical struck up a financing deal with Mérieux Développement that will help fund its work on a steerable sheath for electrophysiology procedures. More

Biotech News

@FierceBiotech: GlaxoSmithKline wins an FDA nod for its new #diabetes drug. More | Follow @FierceBiotech

@JohnCFierce: Little Lexicon posts positive diabetes data as rival pharma giants race ahead. Story | Follow @JohnCFierce

@DamianFierce: J&J's diagnostics business slipped another 7.1% on its way out the door. News | Follow @DamianFierce

@EmilyMFierce: New vaccine could guard against common birth defect-causing virus. Article | Follow @EmilyMFierce

> Merck bags FDA approval for its grass pollen pill Grastek. Story

> Roche adds a slate of PhIII schizophrenia trial failures to bitopertin's obituary. More

> Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy. Article

Pharma News

@FiercePharma: Top-read on FiercePharma Monday: New attention disorder could equal a big new ADHD drug market. But is it legit? Story | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. More from MediaPost | Follow @TracyStaton

@EricPFierce: A Patheon (now DPx) plant that had been up for sale gets a $300M infusion to make Exparel for Pacira. Article | Follow @EricPFierce

@CarlyHFierce: J&J Q1 sales tally 18.1 billion... read more here. Release | Follow @CarlyHFierce

> Roche cancer drugs Perjeta and Kadcyla drive strong Q1 results. Story

> Novartis marks 235 admin jobs for deletion amid companywide restructuring. News

> New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast. More

Biotech Research News

> Essential immune organ regenerated in mice. Story

> 3-D printed tumor mimics cancer better than 2-D model. Piece

> High protein levels linked to cell death in Parkinson's. More

> New vaccine could guard against common birth defect-causing virus. Article

> Plush 'carpets' of Silly Putty ingredient help stem cells grow. Feature

> UCSF rolls out patient database to boost brain research. Item

Pharma Manufacturing News

> Teva recalling more than 1M bottles of generic Cymbalta. Story

> FDA tags yet another Indian drugmaker, Canton Labs, with ban. More

> Plant that Patheon wanted to sell gets $300M investment. Article

> Impax believes manufacturing issues are fixed. News

> FDA bans Baxter plant that makes saline solution. Item

> ViiV recalls 1,000 bottles of Tivicay for cross-contamination. Report

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.